These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Stoner A; Harris A; Oddone F; Belamkar A; Verticchio Vercellin AC; Shin J; Januleviciene I; Siesky B Br J Ophthalmol; 2022 Oct; 106(10):1332-1337. PubMed ID: 34433550 [TBL] [Abstract][Full Text] [Related]
9. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy. Hiett JA; Dockter CA Optom Clin; 1992; 2(4):97-112. PubMed ID: 1286242 [TBL] [Abstract][Full Text] [Related]
10. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects. Nesher R; Ticho U Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130 [TBL] [Abstract][Full Text] [Related]
11. [Trusopt--a new form of drug for treating glaucoma]. Izdebska J Klin Oczna; 1997; 99(3):217-20. PubMed ID: 9456571 [TBL] [Abstract][Full Text] [Related]